EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinical Significance of Different Profiles of anti-Ro Antibodies in Connective Tissue Diseases

Hai-Tao Yang, Xiao-Ping Hong, Jie-Wen Guo, Xiao-Ling Zhong, Rui Liao, Cui-Lian Liu, Li-Xiong Liu, Kai Li, Yu-Lan Chen iD, Dong-Zhou Liu iD

Journal of Immunology Research · 2023

DOI: 10.1155/2023/9195157 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Immunology Research, 2023. Verfasst von Hai-Tao Yang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology and Immunology, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Ho…. Hauptthemen laut MEDLINE: Sjogren's Syndrome, Lupus Erythematosus, Systemic, Myositis. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Basic Research Program of China, National Natural Science Foundation of China, Shenzhen Science and Technology Innovation Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Anti-Ro60 and anti-Ro52 antibodies are associated with different connective tissue diseases (CTDs). However, the clinical significance of anti-Ro antibodies is not always consistent among different global regions. The aim of this study was to investigate the clinical characteristics of patients with anti-Ro antibodies.

Methods

A total of 1596 inpatients with anti-Ro antibodies were included in the study. Demographic, clinical, and serological data were compared between individuals with different profiles of anti-Ro antibodies: patients with anti-Ro52 antibodies alone, patients with anti-Ro60 antibodies alone, and patients with combined anti-Ro52 and anti-Ro60 antibodies.

Results

Of the 1596 patients, 1362 (85.3%) were female, the mean age was 45.5 years, and systemic lupus erythematosus (SLE) (46.0%) and Sjogren’s syndrome (SS) (19.0%) were the most common CTD diagnoses. Among the patients with anti-Ro52 antibodies alone, idiopathic inflammatory myopathy (18.8%) and SLE (17.6%) were the most common CTD diagnoses. The coexistent autoantibodies of this group were significantly lower compared with those of the other two groups, while the presence of anti-Jo1 antibodies were significantly higher compared with those of the other two groups (3.7% vs. 0.6% vs. 1.9%, p = 0.029 ). In addition, the patients with isolated anti-Ro52 antibodies were more likely to suffer from interstitial lung disease (35.5% vs. 11.3% vs. 13.7%, p < 10 − 4 ) and pulmonary arterial hypertension (10.1% vs. 5.3% vs. 3.6%, p = 0.001 ) compared with the other two groups of patients. Compared with patients with isolated anti-Ro52 or anti-Ro60 antibodies, the patients with combined anti-Ro52 and anti-Ro60 antibodies were more likely to suffer from xerophthalmia and xerostomia. Furthermore, hypocomplementemia, hyperglobulinemia, and proteinuria were particularly prevalent in patients with anti-Ro60 antibodies.

Conclusion

Different profiles of anti-Ro antibodies were significantly associated with clinical phenotypic features in CTDs, indicating the potential diagnostic and prognostic value of these antibodies in clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sjogren's SyndromeLupus Erythematosus, SystemicMyositisHumansFemaleMiddle AgedMaleClinical RelevanceAntibodies, AntinuclearAutoantibodiesAutoantigens

Substanzen

Antibodies, AntinuclearAutoantibodiesAutoantigens

Autor:innen und Institutionen

  • Department of Rheumatology and Immunology, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, Guan…
  • The Second Clinical Medical College, Jinan University (Shenzhen People's Hospital), Shenzhen, Guangdong, China.
  • Department of Radiology, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, Guangdong, China.

ORCID-Profile: Yu-Lan Chen, Dong-Zhou Liu

Förderung

  • National Basic Research Program of China
  • National Natural Science Foundation of China
  • Shenzhen Science and Technology Innovation Program

Zitieren

APA

Yang, H. T., Hong, X. P., Guo, J. W., Zhong, X. L., Liao, R., Liu, C. L., Liu, L. X., Li, K., Chen, Y. L., & Liu, D. Z. (2023). Clinical Significance of Different Profiles of anti-Ro Antibodies in Connective Tissue Diseases. Journal of Immunology Research. https://doi.org/10.1155/2023/9195157

Vancouver

Yang HT, Hong XP, Guo JW, Zhong XL, Liao R, Liu CL, et al. Clinical Significance of Different Profiles of anti-Ro Antibodies in Connective Tissue Diseases. Journal of Immunology Research. 2023. doi:10.1155/2023/9195157

BibTeX
@article{Yang2023,
  author = {Yang, Hai-Tao and Hong, Xiao-Ping and Guo, Jie-Wen and Zhong, Xiao-Ling and Liao, Rui and Liu, Cui-Lian and Liu, Li-Xiong and Li, Kai and Chen, Yu-Lan and Liu, Dong-Zhou},
  title = {Clinical Significance of Different Profiles of anti-Ro Antibodies in Connective Tissue Diseases},
  journal = {Journal of Immunology Research},
  year = {2023},
  doi = {10.1155/2023/9195157}
}
Kostenlos starten →